Hurych, Jakub
Oscarsson, Elin
Håkanson, Åsa
Jirků-Pomajbíková, Kateřina
Jirků, Milan
Aronson, Carin Andrén
Cinek, Ondřej
Agardh, Daniel
,
Funding for this research was provided by:
Charles University (CZ.02.2.69/0.0/0.0/18_053/0016976)
National Institute of Virology and Bacteriology (Programme EXCELES, ID Project No. LX22NPO5103, Programme EXCELES, ID Project No. LX22NPO5103)
European Union's Horizon 2020 research and innovation programme (No 874864 HEDIMED, No 874864 HEDIMED, No 874864 HEDIMED)
COST (COST Action CA21105)
Swedish Research Council (Grant/Award No.: 2018-02553)
Lund University
Article History
Received: 23 April 2023
Accepted: 19 October 2023
First Online: 9 November 2023
Declarations
:
: The study was approved by the Ethics Committee of the Medical Faculty, Lund University, on September 8th, 2011 (Dnr 2011/335) and on September 1st, 2021 (Dnr 2021-04470). The study is registered in ClinicalTrials.gov (NCT03176095).
: Not applicable.
: DA is an inventor in a patent application based on the results of the clinical trial but has signed over all legal rights to the patent to Probi AB. Probi AB has developed and supplied the study material (active and placebo products) for the trial as well as financially supported the trial with minor costs for analyzing material. None of the authors are employed by Probi AB and no salaries, consultancy fees, etc., have been paid by Probi AB to the authors in connection with the trial. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.